• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Enveric Biosciences Inc.

    12/5/25 5:40:58 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENVB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    ENVERIC BIOSCIENCES, INC.

    (Name of Issuer)


    Common Stock, $0.01 par value per share

    (Title of Class of Securities)


    29405E505

    (CUSIP Number)


    12/03/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    29405E505


    1Names of Reporting Persons

    Northstrive Fund II LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    25,915.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    25,915.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    25,915.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.34 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) This percentage is based on 596,978 shares of Common Stock of the Issuer that were outstanding as of November 12, 2025, as reported in the Issuer's Form 10-Q filed with the U.S. Securities and Exchange Commission ("SEC") on November 14, 2025. For the avoidance of doubt, the holdings of the Reporting Persons reported herein are as of December 3, 2025. The aggregate percentage ownership of both Reporting Persons is approximately 5.01%.


    SCHEDULE 13G

    CUSIP No.
    29405E505


    1Names of Reporting Persons

    Braeden Lichti
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,005.00
    6Shared Voting Power

    25,915.00
    7Sole Dispositive Power

    4,005.00
    8Shared Dispositive Power

    25,915.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    29,920.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.01 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  (2) This percentage is based on 596,978 shares of Common Stock of the Issuer that were outstanding as of November 12, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on November 14, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ENVERIC BIOSCIENCES, INC.
    (b)Address of issuer's principal executive offices:

    245 First Street, Riverview II, 18th Floor, Cambridge, MA
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Northstrive Fund II LP, a Delaware limited partnership; and (ii) Braeden Lichti ("Mr. Lichti"). The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The securities reported herein are held by Northstrive Fund II LP and Braeden Lichti. Mr. Lichti is the Manager of Northstrive Fund II LP. As such, Mr. Lichti may be deemed to beneficially own the securities held by Northstrive Fund II LP. To the extent Mr. Lichti is deemed to beneficially own such securities, Mr. Lichti disclaims beneficial ownership of these securities for all other purposes.
    (b)Address or principal business office or, if none, residence:

    120 Newport Center Drive, Suite 250 Newport Beach, CA 92660
    (c)Citizenship:

    Northstrive Fund II LP is a Delaware corporation. Mr. Lichti is a citizen of Canada.
    (d)Title of class of securities:

    Common Stock, $0.01 par value per share
    (e)CUSIP No.:

    29405E505
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Rows 5-11 of the cover page for each Reporting Person and is incorporated herein by reference for each Reporting Person.
    (b)Percent of class:

    Northstrive Fund II LP: 4.34% Braeden Lichti: 5.01%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Northstrive Fund II LP: 0 Braeden Lichti: 4,005

     (ii) Shared power to vote or to direct the vote:

    Northstrive Fund II LP: 25,915 Braeden Lichti: 25,915

     (iii) Sole power to dispose or to direct the disposition of:

    Northstrive Fund II LP: 0 Braeden Lichti: 4,005

     (iv) Shared power to dispose or to direct the disposition of:

    Northstrive Fund II LP: 25,915 Braeden Lichti: 25,915

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Northstrive Fund II LP
     
    Signature:/s/ Braeden Lichti
    Name/Title:Braeden Lichti, Manager
    Date:12/05/2025
     
    Braeden Lichti
     
    Signature:/s/ Braeden Lichti
    Name/Title:Braeden Lichti
    Date:12/05/2025
    Get the next $ENVB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENVB

    DatePrice TargetRatingAnalyst
    3/8/2022$7.00 → $0.20Buy → Hold
    Aegis Capital
    7/8/2021$7.00Buy
    Aegis Capital
    6/28/2021$6.00Buy
    Maxim Group
    More analyst ratings

    $ENVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

    Once issued, this new U.S. Patent will expand the scope of Enveric's EVM301 patent portfolio of potential neuroplastogenic molecules for treatment of neuropsychiatric conditions. Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders. The USPTO issues a Notice of Allowance after making the det

    12/9/25 8:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2026"

    Management to meet with investors and potential partners during Biotech Showcase 2026 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company will present and participate in the Sachs Associates 9th Annual Neuroscience Innovation Forum on January 11, 2026 during "J.P. Morgan Week 2026" in San Francisco. Additionally, Enveric will attend Biotech Showcase 2026, which is being held from January 12-14, 2026. During the events, members of Enveric's management team will conduct one-on-one meetings with registered investo

    12/4/25 8:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

    Once issued, this new U.S. Patent will expand the scope of Enveric's EVM401 patent portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions. Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance (NOA) from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM401 Series of molecules being developed as potential treatments for mental health disorders. The USPTO issues a Notice of Allowan

    11/26/25 8:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF INNOVATION OFFICER Facchini Peter J. was granted 24,717 shares, increasing direct ownership by 296% to 33,058 units (SEC Form 4)

    4 - Enveric Biosciences, Inc. (0000890821) (Issuer)

    5/12/25 5:00:16 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Coveney Kevin Michael was granted 74,150 shares, increasing direct ownership by 596% to 86,584 units (SEC Form 4)

    4 - Enveric Biosciences, Inc. (0000890821) (Issuer)

    5/12/25 5:00:20 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Tucker Joseph Edward was granted 98,866 shares, increasing direct ownership by 453% to 120,711 units (SEC Form 4)

    4 - Enveric Biosciences, Inc. (0000890821) (Issuer)

    5/12/25 5:00:06 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    SEC Filings

    View All

    $ENVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ENVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form 424B3 filed by Enveric Biosciences Inc.

    424B3 - Enveric Biosciences, Inc. (0000890821) (Filer)

    12/9/25 8:08:11 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Enveric Biosciences Inc.

    EFFECT - Enveric Biosciences, Inc. (0000890821) (Filer)

    12/9/25 12:15:26 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Enveric Biosciences Inc.

    SCHEDULE 13G - Enveric Biosciences, Inc. (0000890821) (Subject)

    12/5/25 5:40:58 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Pasqualone Frank bought $2,140 worth of shares (1,000 units at $2.14)

    4 - Enveric Biosciences, Inc. (0000890821) (Issuer)

    9/19/23 5:34:00 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences downgraded by Aegis Capital with a new price target

    Aegis Capital downgraded Enveric Biosciences from Buy to Hold and set a new price target of $0.20 from $7.00 previously

    3/8/22 9:32:53 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aegis Capital initiated coverage on Enveric Biosciences with a new price target

    Aegis Capital initiated coverage of Enveric Biosciences with a rating of Buy and set a new price target of $7.00

    7/8/21 9:31:19 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Enveric Biosciences with a new price target

    Maxim Group initiated coverage of Enveric Biosciences with a rating of Buy and set a new price target of $6.00

    6/28/21 8:59:11 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    Financials

    Live finance-specific insights

    View All

    Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

    Product Development Highlights: Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. Started IND-enabling preclinical activities for EB-002 and completed important repeat-dose toxicology studies, genotoxicity studies, and key cardiac, respiratory, and CNS safety pharmacology studies. Corporate and Business Development Highlights: Signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of three classes of compounds from the Company's extensive portfolio of assets. Signe

    3/26/24 7:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights

    Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024 Continued to advance pipeline of small molecule therapeutics for the treatment of mental health disorders, including EB-373 for the treatment of anxiety disorder and EVM301 Series Announced termination of proposed spin-off of cannabinoid clinical development pipeline to publicly traded company; Enveric now engaging with strategic advisors to identify and pursue alternative value-creating opportunities for cannabinoid assets Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of

    5/15/23 9:25:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders

    The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treatments Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the confidential submission of a Form S-1 draft registration statement with the U.S. Securities and Exchange Commission (‘SEC') for the spin-off its cannabinoid clinical development pipeline to a wholly-owned subsidiary, Akos Biosciences, Inc. (‘Akos'),

    11/28/22 7:30:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    Leadership Updates

    Live Leadership Updates

    View All

    Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

    Second biotechnology company to potentially out-license novel compounds from Enveric's portfolio of assets with possible significant milestone payments and royalties Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, is pleased to announce that it has signed two non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for both pharmaceutical and non-pharmaceutical applications for treatment of joint diseases. The term sheets c

    3/19/24 7:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    30+ year pharmaceutical industry veteran joins Enveric's executive team to lead company's financial and capital markets activities. Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today the appointment of Kevin Coveney, CPA, to the position of Chief Financial Officer, effective March 13, 2023. Mr. Coveney brings 30+ years of accounting, finance, and operations experience to Enveric, having previously served as Chief Financial Officer for multiple biotechnology companies. As CFO, Mr. Coveney will be responsibl

    2/28/23 7:30:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Accomplished pharmaceutical industry leader brings to Enveric extensive experience in clinical operations, asset strategy and product development Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today the appointment of Lynn Gallant to the position of Vice President, Clinical Operations. Ms. Gallant brings more than 25 years of clinical operations and trial management experience to Enveric and will work alongside Bob Dagher, M.D., Chief Medical Officer, to oversee the ongoing development of the company's EVM201

    2/23/23 7:33:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

    SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

    11/14/24 4:03:47 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

    SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

    11/13/24 11:18:03 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

    SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

    11/12/24 1:43:47 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care